In the past few decades a revolution in our approach to treating type 2 diabetes has occurred following the recognition that the condition is caused by multiple defects. A range of new treatments are now available, with many more forthcoming, utilising differing mechanisms of action that allow targeted and more effective therapy of this multifactorial disease than ever before. The increasing requirement in the UK to move much of diabetes practice into the community requires much more detailed knowledge of the condition by GPs and practice nurses. In this bespoke book, the authors aim to show how new mechanisms of glucose control and advances in treatments arising from this can tailor treatment to the individual in primary care. This book incorporates the recently published ADA/EASD guidelines and the 2015 update from the National Institute for Health and Clinical Excellence (NICE). Essential reading for the multi-professional diabetes care team, this book should also be of interest to hospital specialists in training.
Professor Barnett is recognised as an International expert in this area and has written many papers and lectured extensively nationally and internationally. He also has acted as expert advisor to NICE on new drugs and has worked with the European Medicines Agency and other related bodies. Indeed, he represented the European Association for the Study of Diabetes (EASD) at the European Medicines Agency on diabetes-related drugs between 2006-2011. He is also presently listed in the top 5 researchers in Type 2 Diabetes worldwide.
Jenny Grice is an accomplished Medical writer and has supported Prof Barnett on many of his projects including co-authoring a bespoke book on New mechanisms in glucose control, published in 2011.
1. Introduction 2. Overview of type 2 diabetes, epidemiology, complications and costs 3. Challenges to glycaemic control ("Deadly Triad" of progressive disease, clinical inertia and poor adherence to management plans), how these can be overcome and how these all interlink 4. Individualised management including individualised lifestyle plans and pharmacotherapy (as emphasised in ADA/EASD Guidelines) 5. Barriers to adherence (poor tolerability- particularly weight gain and hypoglycaemia) and how modern therapies may overcome some of these problems 6. Advantages and disadvantages of new therapies - discussing each in turn, and in context of drug combinations that will be acceptable to patients and help overcome clinical inertia and poor adherence 7. Importance of multi-professional care, education, development of individualised management plans etc.